Clinical trial
Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV…
NCT00095862 · Wiseman Research Initiatives LLC, Industry · Terminated
Key facts
| NCT number | NCT00095862 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers |
| Official title | A Phase 1-2 Study for Stage IV Breast and HER2/Neu Positive Cancers to Evaluate the Safety and Efficacy of a Vaccine Using Whole Cells From the SVBR- 1-GM Cell Line Genetically Engineered To Produce Granulocyte- Macrophage Colony Stimulating Factor |
| Lead sponsor | Wiseman Research Initiatives LLC, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug |
| Interventions | allogeneic GM-CSF-secreting breast cancer vaccine, recombinant interferon alfa, cyclophosphamide |
| Enrollment | 24 |
| Start date | Nov 1, 2004 |
| First posted | Nov 9, 2004 |
| Last update posted | Feb 5, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: